1. Scrip
  2. >>Archive

Mazdutide Consolidates Potential Efficacy Lead In China GLP-1 Obesity Race

 
• By Dexter Jie Yan

Higher-dose mazdutide showed superiority over placebo after 24 weeks of treatment in a Phase II trial in Chinese adults with obesity. The potential best-in-class efficacy profile of the Lilly-originated GLP-1 receptor agonist is expected to help it gain the upper hand in the race for the leadership of the country's obesity market, estimated at $5.5bn in 2030.

China obesity market
$5.5bn domestic market predicted for 2030 enticing Chinese developers of obesity drugs • Source: Shutterstock

Innovent Biologics, Inc. is consolidating a potential efficacy lead for its GLP-1/GCG receptor dual agonist mazdutide in China, moving to grab a share of a domestic obesity market for this class of drugs that could be worth $5.5bn by 2030.

The Suzhou-based biopharma, which licensed the molecule for China from Eli Lilly and Company in 2019, recently announced positive results from a local Phase II study

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.